ArticleBMC cancer2025
Identification of m6 A-regulated ferroptosis biomarkers for prognosis in laryngeal cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Transcriptomics and Mendelian randomization studies reveal the critical role of Stanniocalcin-2 in linking perfluorinated compound-exposure to colorectal cancer.Frontiers in public health · 2026Article
- Non-coding RNAs in laryngeal squamous cell carcinoma: diagnostic biomarkers and emerging exosome-based therapeutic strategies.Cancer cell international · 2025Review
- A novel risk score model incorporating six co-stimulatory molecules for accurate prognosis prediction of laryngeal cancer.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Laryngeal cancer (LC) is a malignant tumor that occurs in the larynx. N6-methyladenosine (m6A) RNA methylation, a pivotal and prevalent epigenetic modification in eukaryotic mRNA, intricately intertwines with ferroptosis, and together, they play a crucial role in the development of LC. Accordingly, further research on related molecular mechanisms and pathology of LC is necessary. Weighted gene co-expression network analysis and correlation analysis were used to identify differentially expressed m6A-related ferroptosis genes in LC. The TCGA-HNSC and GSE65858 datasets were obtained from public databases. The TCGA-HNSC dataset consisted of 110 primary tumor oropharynx samples and 12 control oropharynx samples, while the GSE65858 dataset contained forty-eight primary tumor oropharynx samples. Univariate Cox and least absolute shrinkage and selection operator (LASSO) regression were utilized for feature selection and risk model construction in the TCGA-HNSC dataset. The risk model was validated in the GSE65858 dataset. Then, a nomogram was built based on the independent prognostic factor identified using univariate and multivariate Cox regression in the TCGA-HNSC dataset. Mutation analysis, immune-related analysis, and drug sensitivity prediction were applied to analyze the utility of the risk model in the TCGA-HNSC dataset. Additionally, qRT-PCR and western blot were performed to detect the TFRC, RGS4, and FTH1 expression. Three biomarkers were identified to build a risk model using the univariate Cox and LASSO regression algorithms. Receiver operating characteristic (ROC) analysis verified the accuracy of the risk model. Tumor Immune Dysfunction and Exclusion (TIDE) and Estimation of STromal and Immune cells in MAlignant Tumors using the Expression data (ESTIMATE) algorithm showed a positive relationship between risk score and TIDE or ESTIMATE score. Furthermore, drug sensitivity prediction found that 19 chemotherapy drugs were strongly correlated with a risk score. TFRC, RGS4, and FTH1 exhibited high expression levels in 30 laryngeal carcinoma tissues and cell lines. Notably, TFRC and FTH1 expression levels were significantly associated with patient prognosis. In Conclusion, TFRC, RGS4, and FTH1, were identified as m6A-regulated ferroptosis biomarkers in LC, providing insights into LC treatment and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.